August 1997 SYNLETT 909

A Useful Oxidation Procedure for the Preparation of 3-Alkanoyltetronic Acids

Asmita Mittra, Masayuki Yamashita, Ikuo Kawasaki, Hiromichi Murai, Tomomichi Yoshioka, Shunsaku Ohta* Kyoto Pharmaceutical University, Misasagi-Nakauchicho 5, Yamashinaku, Kyoto 607, Japan Fax +81(75)5954795; E-mail sohta@mb.kyoto-phu.ac.jp

Received 17 April 1997

Abstract: An easy and convenient synthesis of 3-alkanoyl-5-hydroxymethyltetronic acids, the salts of which have inhibitory activity against HIV-1 protease, is described and a new direct route to 1,3-dicarbonylester from cyclic β -ketoester is developed.

In 1994, Roggo and his coworkers isolated six new homologues of sodium salt of 3-alkanoyl-5-hydroxymethyltetronic acids (1a - f) from cultures of the *Actinomycete* strain DSM 7357 and have been found to be inhibitors of HIV-1 protease (Figure 1).^{1,2} We would like to synthesize these acids (1) and their analogs starting from easily available dibenzyl malonate (2). Although there is now a number of procedures for the preparation of simple acyltetronic acids,^{3,4} there is a need to develop more improved methodology which may eventually be applicable to more complex systems. This paper describes an efficient and convenient synthesis of the tetronic acid (1a).

HO 1a)
$$R = (CH_2)_{12}CH_3$$

1b) $R = (CH_2)_{13}CH_3$
1c) $R = (CH_2)_{13}CH(CH_3)_2$
1d) $R = (CH_2)_{14}CH_3$
1e) $R = (CH_2)_{12}CH(CH_3)_2$
1 f) $R = (CH_2)_{12}CH(CH_3)_1$

Figure 1

Epoxidation with m-CPBA in dibenzyl allylmalonate (3) followed by hydrogenolysis afforded the corresponding epoxydicarboxylic acid (5), which was treated with CF₃COOH followed by Ac₂O to give 3-carboxy-5-acetoxymethyl- γ -butyrolactone (6, 86% from 5). Acylation

at C_3 was carried out by the condensation of the magnesium salt of this acid (6) with $CH_3(CH_2)_{12}COIm$ under a mild condition⁵ and 3-tetradecanoyl-5-acetoxymethyl- γ -butyrolactone (7, 48% yield) was obtained as a diastereomeric mixture. Then we attempted to introduce a double bond at C_3 - C_4 position in this novel lactone. For this purpose, phenylselenylation followed by oxidative elimination⁶ of 7 in the presence of an excess of H_2O_2 was carried out. Surprisingly, the tetronic acid (8) was directly obtained as a sole product, and the structure of 8 was confirmed⁷ by NMR, IR, and MS. For the hydrolysis of the acetyl group, the compound (8) was heated at 60°C in MeOH with dil. HCl for 10 hrs. and 1a was obtained as the only isolated product (Scheme 1).

This interesting reaction was applied to several compounds (9 - 13) and the results are summarized in Table 1. Among these 6 samples, cyclic β -ketoesters (7, 9 - 11) gave the desired products (Scheme 1 and Entries 1 - 3), on the other hand, acyclic β -ketoester (12) or β -diester (13) afforded the olefinic product (18, 19, respectively) (Entries 4 and 5).

Thus using an appropriate 1-acylimidazole for acylation of the lactonic acid (6) these 3-alkanoyl-5-hydroxymethyltetronic acids (1b - f) will be able to be prepared readily. Preparation of several analogs of 1, which have an appropriate function on the long side-chain or on the hydroxymethyl group, by application of the present methodology is in progress for evaluation of their HIV-1 protease inhibitory activity. 9

Reagents and conditions : i) NaH, allyl bromide, rt, 12 hrs., 90%. ii) m-CPBA, dry CHCl $_3$, rt, 24 hrs., 98%. iii) H_2 , Pd-C, 97%. iv) a) CF $_3$ COOH, H_2 O-acetone, b) Ac $_2$ O, 86%. v) Mg(OEt) $_2$, CH $_3$ (CH $_2$) $_{12}$ COIm, 48%. vi) a) PhSeCl, AcOEt, 24 hrs., b) 30% H_2 O $_2$ (ca. 15eq.), THF, 2 hrs., 45%. vii) MeOH, dil. HCl, 60°C, 10 hrs., 50%.

Product (Yield)b Condition^a Substrate Entry 1 (51%)9: COOEt COOEt B 10: (10%) (35%); 3 В (65%)COOE COOEt 4 В (49 %) **EtOOC** EtOO0 FtOO Et00 5 В (70%)

Table 1. H₂O₂ Oxidation of β-Dicarbonyl Compounds via the Corresponding Selenides

Condition: A i) PhSeCl/AcOEt, rt, ii) 30% H2O2 (ca. 15 eq.), THF, rt.

B i) PhSeCl/NaH, THF, rt, ii) 30% H2O2 (ca. 15 eq.), THF, rt.

a: Reaction was monitored by TLC.

b: Products were characterized by NMR, IR, MS and/or EA.

References and Notes:

- Roggo, B. E.; Petersen, F.; Delmendo, R.; Jenny, H-B.; Peter, H.
 H.; Rossel J. J. Antibiotics 1994, 47, 136. Roggo, B. E.; Hug P.;
 Moss S.; Raschdorf F.; Peter H. H. J. Antibiotics 1994, 47, 143.
- (2) Dolak, L. A.; Seest, E. P.; Cialdella, J. I.; Bohanon, M. J.(The Upjohn Company): Compounds used for the inhibition of HIVprotease. PCT Int. Appl. 93/04055, Mar. 4, 1993.
- (3) Ley, S. V.; Wadsworth, D. J. Tetrahedron Lett. 1989, 30, 1001.
 Ager, D. J.; Mole, S. J. Tetrahedron Lett. 1988, 38, 4807. Booth,
 P. M.; Fox, C. M. J.; Ley, S. V. Tetrahedron Lett. 1983, 24,
 5143. Booth, P. M.; Fox, C. M. J.; Ley, S. V. J. Chem. Soc. Perkin Trans. 11987, 121 and references cited therein.
- (4) Jerris, P. J.; Wovkulich, P. M.; Smith, III, A. B. Tetrahedron Lett.. 1979, 4517. Bloomer, J. L.; Kappler, F. E. J. Chem. Soc. Perkin Trans. I 1976, 1485. Haynes, L. J.; Stanners, A. H. J. Chem. Soc. 1956, 4103. Lacey, R. N. J. Chem. Soc. 1954, 832.

- (5) Brookes, D. W.; Lu, L. D. L.; Masamune, S. Angew. Chem. Int. Ed. Engl. 1979, 18, 72.
- (6) Reich, H. J.; Renga, J. M.; Reich, I. L. J. Am. Chem. Soc. 1975, 97, 5434 and references cited therein.
- (7) As upon treatment with Ac₂O/pyridine there was no change, while trying to oxidized with PCC, also there was no change.
- (8) Grieco, P. A.; Yokoyama, Y.; Gilman, S.; Nishizawa, M. *J. Org. Chem.* **1977**, *42*, 2034. Kametani, T.; Nemoto, H.; Fukumoto, K. *Heterocycles*, **1977**, *6*, 1365.
- (9) Recently, a total synthesis of 1d has been reported [Sodeoka, M.; Sampe, R.; Kagamizono, T.; Osada, H. Tetrahedron Lett., 1996, 37, 8775].